Biotechnology Scientific Data Repositories Law In Russia.

1. Introduction

Biotechnology Scientific Data Repositories Law in Russia concerns the legal regulation of collecting, storing, processing, preserving, accessing, transferring, and sharing scientific information generated through biotechnology research.

Scientific data repositories are organised digital or physical systems that preserve scientific materials and research information, including:

Genomic and DNA sequencing datasets.

RNA sequencing and gene-expression records.

Clinical-trial and biomedical research data.

Biological sample inventories and biobank records.

Stem-cell and regenerative-medicine research records.

Bioinformatics databases and computational models.

Microbiological and pathogen-related research information.

Genetically modified organism (GMO) research records.

Research publications, experimental results, and laboratory records.

Russia does not have one comprehensive statute exclusively governing all biotechnology scientific data repositories. Instead, their regulation emerges from several legal frameworks dealing with information, personal data, scientific research, healthcare, genetic information, intellectual property, cybersecurity, and biological safety.

The central legal question is how Russia can protect scientific information while allowing legitimate scientific research, institutional collaboration, and technological development.

2. Constitutional and statutory framework

A. Constitution of the Russian Federation

The Constitution provides the foundation for regulating scientific databases and repositories.

Important provisions include:

Article 23: Protects privacy and personal and family secrets.

Article 24: Restricts the collection, storage, use, and dissemination of private information without lawful grounds.

Article 29: Protects freedom of information and scientific expression.

Article 41: Recognises the right to health protection and medical assistance.

Article 44: Protects intellectual property and freedom of scientific and creative activity.

These provisions require a balance between scientific access and individual privacy.

For example, a university conducting genomic research may need to retain DNA sequencing information for future scientific investigations. However, the university must ensure that the information is processed lawfully and that confidential patient information is not improperly disclosed.

B. Federal Law No. 149-FZ of 27 July 2006 — Information, Information Technologies and Information Protection

This law establishes the general legal framework for information systems and databases.

Its relevance to biotechnology repositories includes:

Establishing lawful rules for creating and operating information systems.

Protecting restricted-access scientific information.

Regulating access to electronic databases.

Preventing unlawful disclosure or destruction of information.

Establishing responsibilities for information-system operators.

Scientific institutions operating genomic databases, clinical research repositories, and bioinformatics platforms must consider the law's requirements.

C. Federal Law No. 152-FZ of 27 July 2006 — Personal Data

Central privacy legislation

This is one of the most important laws for biotechnology scientific data repositories.

It regulates the processing of personal information by public institutions, universities, research organisations, laboratories, and private biotechnology companies.

Important provisions:

ProvisionLegal significance
Article 5Purpose limitation, proportionality and data minimisation
Article 6Legal grounds for processing personal data
Article 9Consent to processing
Article 10Special categories of personal data, including health information
Article 11Biometric personal data
Article 18(5)Russian localisation requirements for relevant personal-data processing
Article 19Security measures for personal data
Article 21Correction, blocking and destruction of personal data

Genomic and biomedical repositories may contain information that identifies individuals or reveals their health conditions.

Accordingly, a research institution must distinguish between:

Directly identifiable personal data.

Pseudonymised research information.

Properly anonymised datasets.

Biological samples containing potentially identifiable genetic information.

Removing a person's name does not necessarily make genomic information anonymous. Genetic information can sometimes be linked back to an individual through comparison with other datasets.

D. Federal Law No. 323-FZ of 21 November 2011 — Fundamentals of Health Protection

This legislation is particularly important for repositories containing medical and clinical research information.

Article 13 — Medical confidentiality

Medical confidentiality covers information concerning:

Medical consultations.

Health conditions.

Diagnoses.

Medical examinations.

Treatment and other information obtained during healthcare.

Disclosure for scientific research generally requires written consent under the statutory framework, subject to legally specified exceptions.

Article 91 and Article 91.1

These provisions concern medical information systems and the Unified State Information System in Healthcare (EGISZ).

They are relevant when scientific datasets originate from healthcare institutions or medical information systems.

A biotechnology repository should therefore establish procedures for separating research datasets from identifiable medical records and controlling access to confidential information.

E. Federal Law No. 242-FZ of 3 December 2008 — State Genomic Registration

This legislation regulates the collection, accounting, storage, use, transfer, and destruction of biological material and genomic information for state identification purposes.

Its important features include:

Regulation of state genomic registration.

Establishment of rules for handling biological material.

Processing of genomic information.

Operation of the federal genomic information database.

Restrictions on the use and transfer of genomic information.

The distinction is important: state genomic registration is not the same as an academic or commercial genomic research repository.

A university cannot automatically treat its research database as part of the state genomic registration system.

The law was amended by Federal Law No. 52-FZ of 8 March 2026, with relevant amendments scheduled to enter into force on 7 June 2026.

CIS Legislation+1

 

F. Federal Law No. 180-FZ of 23 June 2016 — Biomedical Cellular Products

This legislation governs the development, preclinical research, clinical trials, production, quality control, storage, transportation, and other activities involving biomedical cellular products.

It is particularly relevant to repositories storing:

Human cellular material.

Cell lines.

Biological materials used to prepare cellular products.

Samples associated with regenerative medicine.

Article 36 addresses storage requirements and requires relevant biological materials and cellular products to be stored under conditions that preserve their biological properties and prevent contamination.

An important qualification is that Article 1(2) excludes certain activities involving human cells and tissues for scientific and educational purposes from the law's scope. Therefore, not every university biological collection is automatically governed by the biomedical-cell-product regime.

CIS Legislation+1

 

3. Specific legal regulation of biotechnology scientific repositories

A. Federal Law No. 127-FZ — Science and State Scientific and Technical Policy

This legislation provides the general framework for scientific and technological activities.

It is relevant to:

Scientific research institutions.

State-funded biotechnology projects.

Research collaboration.

Scientific infrastructure.

Dissemination of research results.

Institutional responsibility for research activities.

A repository established by a publicly funded research institution must consider the conditions attached to its funding, research programme, and applicable rules governing scientific information.

B. National standard GOST R ISO 20387-2021

Biobanking quality standard

This standard is titled Biotechnology — Biobanking — General Requirements.

It provides technical and organisational requirements for biobanks.

Important areas include:

Biological-material acceptance procedures.

Sample identification and authentication.

Storage conditions and environmental monitoring.

Traceability of samples and associated data.

Staff competence and responsibility.

Quality-management procedures.

Distribution and transfer of biological materials.

Documentation and emergency procedures.

It is particularly important that biological samples and associated information remain traceable throughout their storage and use.

The standard also addresses material-transfer agreements (MTAs) and data-transfer agreements (DTAs).

It should be understood as a technical standard, not an independent statute imposing every requirement on every scientific database. Its legal force depends on the applicable regulatory framework, contractual incorporation, and whether compliance is otherwise mandatory.

internet-law.ru+2

 

C. GOST R 71251-2024 — Biotechnology: Biobanking Terminology and Definitions

This national standard provides terminology for modern biobanking.

It recognises different types of biobanks, including:

Research biobanks.

Population biobanks.

Diagnostic biobanks.

Therapeutic biobanks.

Tissue banks.

Cell banks.

Biodiversity biobanks.

It also recognises electronic catalogues of biological collections.

An important concept is the distinction between biological samples and their associated data. An electronic catalogue may contain descriptions and sample identifiers, but its design must avoid exposing personal data improperly.

The standard is useful for establishing consistent terminology in institutional policies, repository contracts, and research documentation.

ГАРАНТ+1

 

D. Ministry of Health Order No. 842n of 20 October 2017

This order establishes requirements for the organisation and operation of biobanks and storage rules for biological materials used in biomedical cellular products.

It addresses:

Organisation of biobank facilities.

Storage infrastructure.

Temperature and environmental conditions.

Prevention of infection and contamination.

Preservation of biological properties.

Storage management and operational procedures.

Its scope must be read together with Federal Law No. 180-FZ. It should not be treated as a universal licensing regime for every scientific data repository in Russia.

Consultant Plus+1

 

4. Collection and storage of scientific data

Russian biotechnology repositories must establish lawful procedures for collecting and storing scientific information.

A. Collection of genomic data

Genomic information may be collected through:

DNA sequencing.

Genetic screening.

Genome-wide association studies.

Clinical genetic testing.

Research involving inherited diseases.

Population-genetics investigations.

The institution should document the purpose of collection, legal basis, consent where required, and permitted future uses.

For example, if a research organisation collects DNA samples from 2,000 volunteers to investigate hereditary diseases, it should specify whether the samples and associated genomic data may also be used in future research.

B. Storage and preservation

Repositories must protect the integrity and confidentiality of scientific datasets.

Appropriate safeguards include:

Encryption of sensitive datasets.

Role-based access controls.

Secure backup systems.

Access logs and audit trails.

Separation of identifying information from research datasets.

Periodic security assessments.

Documented retention and deletion policies.

For physical biobanks, appropriate temperature control, sample authentication, contamination prevention, and emergency storage arrangements are also important.

C. Data ownership and intellectual property

Scientific repositories create complicated questions concerning ownership and control.

For example:

Who controls a genomic dataset generated by a publicly funded university?

Can a biotechnology company commercialise research findings?

Can researchers reuse datasets generated by another institution?

Does a donor retain rights over information derived from their biological material?

Russian intellectual-property law, particularly Part IV of the Civil Code, protects qualifying scientific works, databases, software, and inventions.

Article 1260 of the Civil Code addresses copyright protection for compilations and databases.

Article 1334 provides a sui generis right of a database maker in qualifying cases where substantial investment has been made in creating a database.

Article 1228 concerns authorship and the rights of creators.

However, intellectual-property rights in a database do not automatically establish ownership of the personal data or biological samples contained within it.

This distinction is essential in biotechnology research.

5. Sharing and transferring scientific data

Scientific repositories frequently exchange information between universities, hospitals, laboratories, and biotechnology companies.

Such sharing raises several legal issues.

A. Domestic data sharing

Domestic sharing should be based on:

A lawful processing ground.

Appropriate consent where required.

Research collaboration agreements.

Data-transfer agreements.

Confidentiality obligations.

Defined access permissions.

For example, a university may share properly protected genomic research data with a Russian biotechnology company for the development of diagnostic technologies.

The parties should specify the permitted purpose, security responsibilities, retention period, and restrictions on onward disclosure.

B. International data transfers

Cross-border transfers are particularly complicated when genomic or clinical information relates to identifiable individuals.

Under Article 12 of Federal Law No. 152-FZ, the operator must comply with applicable cross-border personal-data transfer requirements, including the notification procedure and restrictions applicable to the destination country.

Article 18(5) is also important because relevant personal-data collection, recording, systematisation, accumulation, storage, updating, and retrieval operations involving Russian citizens' personal data are subject to Russian database-localisation requirements, subject to statutory exceptions.

Consequently, a Russian biotechnology company cannot assume that it may freely transfer an entire genomic repository to a foreign cloud provider.

The legal assessment should consider:

Whether the dataset contains personal data.

Whether genetic information can identify an individual.

Whether the transfer is permitted under Article 12.

Whether the recipient country satisfies the relevant legal conditions.

Whether separate research and contractual permissions are required.

Whether localisation requirements have been satisfied.

C. International scientific collaboration

International biotechnology projects may involve:

Joint genomic databases.

Clinical-trial repositories.

Pathogen research databases.

Artificial-intelligence training datasets.

Shared biological-resource collections.

Researchers should distinguish the transfer of physical biological samples from the transfer of electronic scientific information. Different regulatory and contractual requirements may apply.

6. Cybersecurity and protection against unlawful access

Scientific repositories are attractive targets for cyberattacks because they may contain valuable genomic information, unpublished discoveries, clinical information, and commercially sensitive research.

Relevant legislation includes:

Federal Law No. 149-FZ: Provides the general framework for information protection.

Federal Law No. 152-FZ, Article 19: Requires operators to take organisational and technical measures to protect personal data.

Federal Law No. 187-FZ of 26 July 2017: Regulates the security of critical information infrastructure.

Where a biotechnology institution or its information system falls within the statutory definition and classification requirements, the critical-information-infrastructure regime may apply.

Potential legal violations include:

Unauthorised access to genomic databases.

Theft of clinical-trial information.

Disclosure of confidential genetic records.

Destruction or manipulation of scientific data.

Unlawful commercial exploitation of research datasets.

Depending on the circumstances, administrative, civil, disciplinary, and criminal liability may arise.

7. Important case laws and judicial decisions

Relevant judicial authorities

There is an important limitation in Russian biotechnology repository jurisprudence: there is no well-established body of reported Russian judgments directly determining all aspects of ownership, long-term storage, donor consent, and commercial reuse of human genomic research repositories.

Nevertheless, Russian constitutional decisions and European human-rights judgments concerning Russian authorities provide important legal principles.

Case 1. Constitutional Court of Russia — Judgment No. 1-P of 13 January 2020

RUSSIAN CONSTITUTIONAL COURT · 2020

Subject: Medical confidentiality and access to medical records of deceased patients.

Facts:

The Constitutional Court considered the legal uncertainty surrounding access to the medical records of a deceased patient by the spouse, close relatives, and persons identified by the patient.

Legal issue:

Whether the existing legal framework adequately regulated access to medical records after a patient's death.

Decision:

The Court found the relevant legal provisions constitutionally deficient to the extent that they did not establish sufficiently clear conditions and procedures for access.

It directed that, pending legislative clarification, medical organisations should provide access to relevant medical documents to qualifying persons, unless the deceased patient had prohibited disclosure during their lifetime.

Importance for scientific repositories:

This judgment is relevant to repositories containing historical clinical information.

It demonstrates that:

Medical confidentiality does not disappear simply because information is stored electronically.

The legal status of medical records must be considered after the patient's death.

Access rights must be balanced against confidentiality.

Research institutions cannot assume that death automatically makes medical records freely available.

The judgment is particularly significant for long-term clinical and genomic research archives.

Consultant Plus+2

 

Case 2. Avilkina and Others v. Russia (2013)

EUROPEAN COURT OF HUMAN RIGHTS · APPLICATION NO. 1585/09 · 6 JUNE 2013

Subject: Unauthorised disclosure of confidential medical information.

Facts:

The applicants were members of a religious community who had refused blood transfusions.

Russian prosecutorial authorities requested information concerning their medical treatment, and confidential medical information was disclosed.

Legal issue:

Whether disclosure of sensitive medical information without adequate justification violated the applicants' right to privacy under Article 8 of the European Convention on Human Rights.

Decision:

The European Court found a violation of Article 8.

It emphasised the importance of medical confidentiality and the need for convincing justification when public authorities seek access to private medical information.

Importance for scientific repositories:

The judgment establishes an important principle: medical information cannot be disclosed merely because a public authority or another organisation requests it.

For biotechnology repositories, this means:

Researchers should not provide identifiable clinical information without a lawful basis.

Government access should follow applicable statutory procedures.

Repository administrators should maintain access controls.

Sensitive medical information requires heightened confidentiality.

Legal significance: This is a European Court judgment against Russia, not a judgment of the Russian Supreme Court. Russia ceased to be a party to the European Convention on Human Rights on 16 September 2022. The judgment remains an important historical authority concerning the conduct of Russian authorities during the period of the Convention's applicability.

Law Gratis+1

 

Case 3. Constitutional Court of Russia — Judgment No. 31-P of 13 July 2022

RUSSIAN CONSTITUTIONAL COURT · 2022

Subject: Medical information systems and confidentiality of psychiatric medical records.

Facts:

The Court examined provisions of the healthcare legislation concerning the obligations of medical organisations to maintain and provide information relating to healthcare activities.

The case concerned the interaction between medical documentation, access to information, and confidentiality.

Legal issue:

How should statutory obligations to maintain medical records be reconciled with the confidentiality of sensitive health information?

Legal importance:

The Court discussed the relationship between healthcare information systems, medical confidentiality, and the Personal Data Law.

It recognised that health information is subject to special protection and that processing without written consent must fall within an applicable statutory exception.

Application to biotechnology repositories:

This decision is relevant to repositories storing psychiatric, neurological, and other sensitive clinical research data.

It supports the following principles:

Sensitive medical information must be processed under a lawful basis.

Healthcare information systems must preserve confidentiality.

Access to records must be governed by legal requirements.

Scientific usefulness alone does not justify unrestricted access.

Consultant Plus+1

Case 4. Y.G. v. Russia

EUROPEAN COURT OF HUMAN RIGHTS · PERSONAL DATA AND PRIVATE LIFE

This case concerned the retention of information relating to an individual's criminal record in a government database and the individual's privacy rights.

Its relevance to biotechnology is indirect.

The broader principle is that the retention of personal information in official databases must have a sufficiently clear legal basis and appropriate safeguards.

For genomic repositories, this principle is relevant when considering:

Duration of data retention.

Access by public authorities.

Correction of inaccurate information.

Restrictions on secondary use.

Protection against excessive retention.

It should not be presented as a case directly deciding the legality of a scientific genomic repository.

collab.dpa.gr

 

Case 5. S. and Marper v. United Kingdom (2008)

EUROPEAN COURT OF HUMAN RIGHTS · GRAND CHAMBER · APPLICATION NOS. 30562/04 AND 30566/04

Subject: Retention of DNA profiles and cellular samples.

Facts:

The applicants challenged the indefinite retention of their fingerprints, DNA profiles, and cellular samples following criminal proceedings that had not resulted in convictions.

Legal issue:

Whether retaining DNA information and biological samples without adequate differentiation and safeguards violated Article 8.

Decision:

The Grand Chamber found a violation of Article 8.

Importance for Russia:

Although this was not a Russian case, it offers a useful comparative human-rights framework for evaluating:

Indefinite retention of DNA samples.

Proportionality of genomic data storage.

Differences between DNA profiles and biological samples.

Privacy risks associated with long-term repositories.

It is persuasive comparative material rather than binding Russian domestic precedent.

8. Liability for violations involving scientific data repositories

Russian law provides several possible forms of liability.

Type of liabilityLegal frameworkExamples
Civil liabilityCivil CodeCompensation for damage and unlawful disclosure
Administrative liabilityAdministrative Offences Code, Article 13.11Violations of personal-data processing requirements
Criminal liabilityCriminal Code, Article 137Unlawful collection or dissemination of private information
Criminal liabilityCriminal Code, Article 272Unlawful access to computer information
Criminal liabilityCriminal Code, Article 274.1Unlawful interference with critical information infrastructure, where applicable
Disciplinary liabilityEmployment legislationResearch misconduct and breach of institutional duties

A. Unlawful disclosure of genetic information

Suppose a biotechnology company publishes identifiable genetic information without an appropriate legal basis.

Possible consequences include administrative penalties, civil claims, and criminal liability where the relevant statutory elements are established.

B. Destruction of scientific datasets

Suppose a laboratory employee deliberately deletes a university's genomic research database.

Depending on the circumstances, the conduct may constitute unlawful interference with computer information or another offence.

C. Misuse of biological samples

Suppose a research institution uses donated biological material for a purpose outside the applicable consent or other legal authorisation.

The institution may face contractual, civil, administrative, or other legal consequences depending on the applicable legislation and facts.

9. Major legal challenges

Several unresolved or developing issues deserve particular attention.

1. Donor consent and future research

Consent for one research project does not necessarily authorise every future use of a biological sample or associated dataset.

2. Genetic privacy

Even pseudonymised genomic information may create re-identification risks.

3. Commercialisation

The commercial use of scientific datasets raises questions concerning intellectual-property rights, donor permissions, contractual rights, and personal-data protection.

4. International transfers

International research collaboration must reconcile scientific openness with Russian localisation and cross-border transfer requirements.

5. Artificial intelligence

Biotechnology repositories increasingly supply data for machine-learning systems. Secondary use of genomic or clinical information raises questions about purpose limitation, consent, security, and algorithmic accountability.

6. Long-term preservation

Scientific information may remain useful for decades. However, institutions must reconcile scientific preservation with applicable data-retention, deletion, and privacy obligations.

7. Public access versus confidentiality

Scientific reproducibility requires access to research results, but unrestricted disclosure of identifiable medical or genetic information may violate legal protections.

10. Practical compliance framework for Russian biotechnology institutions

A university, hospital, or biotechnology company establishing a scientific data repository should implement the following measures.

Compliance areaRecommended institutional measure
Data collectionDocument lawful grounds and research purposes
Donor protectionObtain appropriate informed consent
Data classificationSeparate personal, genomic, clinical and non-personal data
StorageUse secure and monitored infrastructure
AccessEstablish role-based permissions
Research sharingExecute data-transfer agreements
Biological samplesMaintain sample inventories and traceability
International transfersAssess Articles 12 and 18(5) of Law 152-FZ
CybersecurityImplement Article 19 safeguards
RetentionAdopt documented retention and deletion schedules
AccountabilityConduct periodic compliance audits

11. Critical legal analysis

The Russian framework demonstrates that biotechnology scientific data repositories are regulated through multiple overlapping legal regimes rather than one comprehensive repository-specific statute.

Three important legal tensions emerge.

First: Scientific freedom versus personal privacy.

Scientific researchers require access to extensive datasets to investigate genetic diseases and develop new treatments. However, privacy legislation and medical confidentiality restrict the processing and disclosure of identifiable information.

Second: Research preservation versus individual rights.

Scientific repositories are designed for long-term preservation. Personal-data legislation, however, requires institutions to consider the purpose, necessity, and lawful duration of data retention.

Third: Scientific collaboration versus national regulatory control.

International biotechnology research requires the exchange of genomic and clinical information. Russian data-localisation and cross-border transfer requirements can create additional legal and operational challenges.

The constitutional decisions and human-rights cases discussed above provide important interpretative principles, although they do not establish a comprehensive judicial doctrine specifically governing biotechnology repositories.

12. Conclusion

Biotechnology Scientific Data Repositories Law in Russia is an evolving area of information, biotechnology, healthcare, and intellectual-property regulation.

The principal legislative framework consists of:

Constitution of the Russian Federation.

Federal Law No. 149-FZ on Information.

Federal Law No. 152-FZ on Personal Data.

Federal Law No. 127-FZ on Science and State Scientific and Technical Policy.

Federal Law No. 323-FZ on Healthcare.

Federal Law No. 242-FZ on State Genomic Registration.

Federal Law No. 180-FZ on Biomedical Cellular Products.

Civil Code of the Russian Federation.

GOST R ISO 20387-2021.

GOST R 71251-2024.

The most important judicial authorities include Constitutional Court Judgments No. 1-P (2020) and No. 31-P (2022), together with Avilkina and Others v. Russia (2013) and the comparative decisions in S. and Marper v. United Kingdom (2008).

Ultimately, Russian biotechnology institutions must ensure that scientific datasets are collected lawfully, stored securely, shared responsibly, and preserved in accordance with applicable privacy, healthcare, scientific, and intellectual-property requirements.

13. Important legal sources and further reading

The following sources are useful for academic research and verification of the statutory framework:

Federal Law No. 152-FZ — Personal Data.

Federal Law No. 242-FZ — State Genomic Registration.

Federal Law No. 180-FZ — Biomedical Cellular Products.

Constitutional Court Judgment No. 1-P of 13 January 2020.

Constitutional Court Judgment No. 31-P of 13 July 2022.

GOST R ISO 20387-2021 — Biobanking General Requirements.

GOST R 71251-2024 — Biobanking Terminology.

Ministry of Health Order No. 842n — Biobank Requirements.

Academic research note: Before relying on this analysis in litigation or publication, check the consolidated Russian-language legislation and subsequent amendments. In particular, distinguish regulations applicable to biomedical cellular-product biobanks from those applicable to research-only collections and digital scientific repositories.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT